UK first to approve CRISPR treatment for diseases: what you need to know

The landmark decision could transform the treatment of sickle-cell disease and β-thalassaemia — but the technology is expensive. The landmark decision could transform the treatment of sickle-cell disease and β-thalassaemia — but the technology is expensive.